All In Biotech

Drug Trial Radar · NCT06757010

A Study of NE3107 in Early Parkinson's

A Double-Blind, Randomized, Placebo-controlled, Study of NE3107 in Subjects With Early Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

57

Actual

Start

Mar 26, 2025

Primary completion

May 1, 2026

Study completion May 31, 2026

Sponsor

Lead sponsor
BioVie Inc.Industry
Sponsor type
Industry
First posted
Jan 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. The main questions it aims to answer are: * Will bezisterim decrease movement symptoms of Parkinson's disease? * What medical problems do participants have when taking bezisterim? Researchers will compare the effects of bezisterim treatment to placebo (a look-alike substance that contains no drug) to see if bezisterim works to treat movement symptoms of Parkinson's disease. Participants will * have a physical examination that includes an electrocardiogram * take drug or placebo twice daily for four months * visit a clinical site or receive an at home visit seven times over the course of five months

Conditions

  • Parkinsons Disease (PD)

Interventions

  • NE3107Drug

    NE3107 20 mg BID

  • PlaceboDrug

    Placebo BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Monocyte Lymphocyte Ratio (MLR)Time frame: 12 Weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Quest Research Institute

    Farmington Hills, Michigan

  • Dent Neurologic

    Amherst, New York

  • Science 37 (Nationwide Site)

    Morrisville, North Carolina

  • NeuroScience Research Center, LLC

    Canton, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.